Instituto Valenciano de Oncologia-ko ikertzaileekin lankidetzan egindako argitalpenak (6)

2021

  1. Current treatments for BCG failure in non-muscle invasive bladder cancer (NMIBC)

    Actas Urologicas Espanolas, Vol. 45, Núm. 2, pp. 93-102

2015

  1. Sequential combination of mitomycin C plus bacillus calmette-guérin (BCG) is more effective but more toxic than BCG alone in patients with non-muscle-invasive bladder cancer in intermediate- and high-risk patients: Final outcome of CUETO 93009, a randomized prospective trial

    European Urology, Vol. 67, Núm. 3, pp. 508-516

2013

  1. Tratamiento del tumor vesical no músculo infiltrante frente al problema de disponibilidad de bacilo de Calmette-Guerin. Consenso de un panel de expertos españoles

    Actas Urologicas Espanolas, Vol. 37, Núm. 7, pp. 387-394

2009

  1. Predicting Nonmuscle Invasive Bladder Cancer Recurrence and Progression in Patients Treated With Bacillus Calmette-Guerin: The CUETO Scoring Model

    Journal of Urology, Vol. 182, Núm. 5, pp. 2195-2203

2007

  1. A Multicentre, Randomised Prospective Trial Comparing Three Intravesical Adjuvant Therapies for Intermediate-Risk Superficial Bladder Cancer: Low-Dose Bacillus Calmette-Guerin (27 mg) versus Very Low-Dose Bacillus Calmette-Guerin (13.5 mg) versus Mitomycin C

    European Urology, Vol. 52, Núm. 5, pp. 1398-1406

2005

  1. Has a 3-fold decreased dose of Bacillus Calmette-Guerin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose? Results of a prospective randomized trial

    Journal of Urology, Vol. 174, Núm. 4 I, pp. 1242-1247